Discrepancy between short-term and long-term effects of bone marrow-derived cell therapy in acute myocardial infarction: a systematic review and meta-analysis

Table 3 Major adverse events

Event			Cell therapy group		Control group		Odds ratio
Event	Follow-up	Study (participants)	Total event	Participants	Total event	Participants	(M-H, random)	95 % CI
All-cause mortality	6 mo	18 (1284)	10	707	6	577	1.08	0.42–2.81
	1 yr	8 (286)	5	174	4	112	0.89	0.24–3.32
	3 yr	5 (432)	9	228	11	204	0.58	0/22–1.56
	5 yr	5 (458)	10	226	22	232	0.45	0.21–0.97
Heart failure admission	6 mo	9 (970)	10	512	15	458	0.56	0.24–1.31
	1 yr	3 (83)	2	42	0	41	3.07	0.30–30.96
	2 yr	4 (333)	4	179	14	154	0.15	0.04–0.50
	3 yr	6 (577)	11	284	17	293	0.65	0.30–1.44
Recurrence of ischemic heart disease	6 mo	14 (1214)	29	663	37	551	0.57	0.32–1.00
	1 yr	2 (81)	0	48	1	33	0.14	0.01–3.68
	2 yr	6 (373)	6	199	11	174	0.68	0.18–2.56
	3 yr	6 (528)	9	262	11	266	0.81	0.33–2.00
Revascularization/restenosis	6 mo	14 (1212)	98	662	92	550	0.87	0.63–1.22
	1 yr	4 (156)	2	87	4	69	0.37	0.07–1.89
	2 yr	6 (373)	36	199	45	174	0.65	0.39–1.10
	3 yr	6 (577)	62	284	76	293	0.77	0.52–1.15
Cerebral vascular accident (CVA)	1 yr	2 (150)	1	68	2	82	0.69	0.08–5.81
Cerebral vascular accident (CVA)	2 yr	3 (500)	5	248	10	252	0.5	0.16–1.50

ISSN: 1757-6512